Aside from concurrent inhibition of mTOR and CFTR, numerous therapies targeting one of the key processes in the pathogenies of ADPKD are in development or in clinical trials [21, 22, 23, 24]. This evidence concerns the gene MTOR and autosomal dominant polycystic kidney disease.